TITLE

Anti-inflammatory drugs: What is safe?

AUTHOR(S)
Karsh, Jacob
PUB. DATE
August 2006
SOURCE
CMAJ: Canadian Medical Association Journal;8/29/2006, Vol. 175 Issue 5, p449
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article offers a view on the safety of traditional nonsteroidal anti-inflammatory drugs (NSAID). There are risks associated with the use of cyclooxygenase-2 inhibitors. It is important to evaluate patients when prescribing NSAID. Patients should be informed about anti-inflammatory therapy before they decide to undergo such type of medication.
ACCESSION #
22278173

 

Related Articles

  • Independent Nurse: COX-2s could be best for some arthritis.  // GP: General Practitioner;2/10/2006, p69 

    This article reports that according to researchers from Imperial College, London, England, Cyclooxygenase-2 inhibitors may still be the best option for treating some forms of arthritis. They reviewed over 100 studies and found that although the drugs were associated with an increase in the risk...

  • Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. Mamdani, Muhammad; Rochon, Paula; Laupacis, Andreas; Anderson, Geoffrey // CMAJ: Canadian Medical Association Journal;11/12/2002, Vol. 167 Issue 10, p1125 

    Examines the impact of listing cyclooxygenase-2 (COX-2) inhibitors on the Ontario Drug Benefit (ODB) formulary relative to the costs of overall nonsteroidal anti-inflammatory drugs (NSAID). How ODB first listed COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) as limited use;...

  • Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous. Roumie, Christianne L.; Arbogast, Patrick G.; Mitchel, Edward F.; Griffin, Marie R. // JGIM: Journal of General Internal Medicine;Oct2005, Vol. 20 Issue 10, p879 

    Objective: To describe the use of coxibs outside of licensed indications and recommended dosing ranges including rofecoxib 50 mg, valdecoxib 20 to 40 mg, and celecoxib 400 mg. Design: Cross-sectional study of coxib utilization in 2002 and 2003 and retrospective cohort analysis of new users....

  • Coxib withdrawal reduced GI prophylaxis rates.  // PharmacoEconomics & Outcomes News;8/22/2009, Issue 585, p6 

    The article reports on a study in the U.S. on the link between COX-2 inhibitor withdrawal and gastroprotective nonsteroidal anti-inflammatory drug (NSAID) prescriptions. NSAID and gastroprotective agents were used to treat rheumatoid and psoriatic arthritis. A decrease in gastroprotective...

  • The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Brophy, J. M.; Lévesque, I. E.; Zhang, B. // Heart;Feb2007, Vol. 93 Issue 2, p189 

    Background: Cyclo-oxygenase-2 selective inhibitors have been associated with cardiovascular side effects, but previous studies have generally excluded people with previous myocardial infarction, thereby limiting our knowledge of their cardiotoxicity in this population. Objectives: To determine...

  • Entire COX-2s class increases risk of MI.  // GP: General Practitioner;4/21/2006, p4 

    The article reports that newer Cyclooxygenase-2 inhibitors increase the risk of myocardial infarction (MI) as much as rofecoxib. Researchers compared nonsteroidal anti-inflammatory agents (NSAIDs) use in 3,643 cases of acute MI with 13,918 controls matched for age, sex and general practice. It...

  • Review: Risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin, but not celecoxib. Bradley, Colin P. // ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p24 

    The article offers information on a research study regarding risk factors that lead to cardiovascular (CV) events in patients using cyclo-oxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs. The study was conducted by researcher P. McGettigan, and published in the "Journal of the...

  • Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors. Patrício, José; Barbosa, Jorge; Ramos, Rui; Antunes, Nuno; Melo, Pedro // Clinical Drug Investigation;2013, Vol. 33 Issue 3, p167 

    Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in clinical practice, and are considered a first-line option for pain management. However, non-selective NSAIDs (nsNSAIDs) and new generation NSAIDs named cyclo-oxygenase-2 inhibitors (coxibs) are very different from one another...

  • Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. Ferraz-Amaro, Iván; Machín, Sergio; Carmona, Loreto; González-Alvaro, Isidoro; Díaz-González, Federico // Reumatologia Clinica;nov/dic2009, Vol. 5 Issue 6, p252 

    Objective: The aim of this study was to determine the prescription pattern and the safety profile of nonsteroidal anti-inflammatory drugs (NSAID). including cyclooxygenase-2 inhibitors (COXIB) in patients with rheumatoid arthritis (RA) under a real life clinical setting. Patients and Methods:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics